Federation des caisses Desjardins du Quebec’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Federation des caisses Desjardins du Quebec’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-3,231	Closed	-$170K	–	2249
2018 Q1	$170K	Sell	3,231 -1,128	-26%	-$65.6K	﹤0.01%	1064
2017 Q4	$233K	Hold	4,359	–	–	﹤0.01%	1001
2017 Q3	$260K	Buy	4,359 +1,791	+70%	+$108K	﹤0.01%	959
2017 Q2	$203K	Buy	+2,568	New	+$210K	﹤0.01%	972

Other funds holding EGRX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

HEC

Hudson Executive Capital New York $151M AUM 60.14% 1-Year Est. Return

IAM

Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

JAM

JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return

Federation des caisses Desjardins du Quebec's EGRX Position: Q2 2018 in Review

Federation des caisses Desjardins du Quebec sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q2 2018, closing a stake of 3,231 shares — an estimated $170K sold.

Federation des caisses Desjardins du Quebec first reported a position in EGRX in Q2 2017 and held it in 4 quarters. The position peaked at $260K in Q3 2017. 183 funds tracked by Wall St. Rank hold EGRX as of Q2 2018.

Federation des caisses Desjardins du Quebec reported no remaining Eagle Pharmaceuticals, Inc. position as of Q2 2018 after selling out during the quarter.
Federation des caisses Desjardins du Quebec sold 3,231 Eagle Pharmaceuticals, Inc. shares in Q2 2018, an estimated $170K.
Federation des caisses Desjardins du Quebec first reported a position in Eagle Pharmaceuticals, Inc. in Q2 2017 and held it in 4 quarters.
Federation des caisses Desjardins du Quebec's Eagle Pharmaceuticals, Inc. position peaked at $260K in Q3 2017.
183 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q2 2018.

Based on Federation des caisses Desjardins du Quebec's 13F filing for Q2 2018, filed 30 Aug 2024.